“Exceptional” Approval Could Replace “Accelerated” For Rare Cancer Drugs

An "exceptional" approval process should be carved out of the accelerated approval program for products targeting rare cancers where there is little likelihood of completing confirmatory trials, members of FDA's Oncologic Drugs Advisory Committee recommended